Mathematical modeling combined with experiment has led to increased understanding of the processes that underlie HIV-1 infection and the development of improved therapies. Nevertheless HIV has not been eradicated from infected individuals. Here we propose to develop new models of HIV infection that will help inform vaccine and microbicide development. The models will incorporate both cell-mediated and humoral immune responses to infection, and aim toward understanding the roles that CD8 T cells and antibodies play in the natural defense against HIV. We will also develop stochastic models of the first events in infection in order to gain insight into the earliest processes that occur when virus first enters a person. Some of the early events in infection involve depletion of CD4+ T cells in the gut. These events will be modeled as well as the dynamics of reconstitution of CD4 T cells in the gut due to the effects of antiretroviral therapy. Lastly, models with multiple organs, such as gut, liver, lymph nodes, etc. will be used to understand how HIV distributes throughout the body and how it is cleared at different sites in the body. Infection by hepatitis C virus (HCV) and hepatitis B virus (HBV) continue to cause liver failure and hepatocellular carcinoma in infected individuals. Understanding the basis of pathogenesis and the development of potent antiviral therapies for these viruses lag behind our advances in HIV. We propose to expand our efforts in modeling HCV and HBV in vivo kinetics and the effects of antiviral therapy. In the case of HCV we propose to focus on modeling new treatments with specifically targeted anti-HCV agents, such as HCV polymerase and protease inhibitors. With these new agents the development of resistance is a great concern and we will expand models of viral kinetics and treatment that we have previously developed and validated so as to incorporate viral mutation and the development of drug resistance. We will also perform calculations aimed at understanding how prevalent pre-existing drug resistance mutations should be as well as use modeling to develop better treatment strategies, Lastly, for the case of HBV, we aim to understand why HBV infection can be cleared during primary infection in adults. We will develop models of primary HBV infection that include both non-cytolytic responses and antibody responses. We also plan to develop a new generation of on treatment models that follow not only the dynamics of HBV DNA but also HBe antigen and Hbs antigen, molecules that are used in clinical practice to access response to therapy but whose dynamics have been well studied.

Public Health Relevance

The goals of this project are to expand our understanding of viral and lymphocyte dynamics as they pertain to HIV/AIDS as well as to hepatitis B and hepatitis C virus infections. These three viruses are major public heath threats with HIV currently infecting about 33 million people world- wide, while hepatitis B and C currently infect about 300 million and 170 million people, respectively. By developing mathematical models of these infections and their treatment we aim to improve our basic understanding of disease pathogenesis and improve protocols for antiviral therapy.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Research Project (R01)
Project #
8R01OD011095-21
Application #
8292885
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Chang, Michael
Project Start
1991-04-19
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
21
Fiscal Year
2012
Total Cost
$476,303
Indirect Cost
$229,617
Name
Los Alamos National Lab
Department
Type
DUNS #
175252894
City
Los Alamos
State
NM
Country
United States
Zip Code
87545
Canini, Laetitia; Chatterjee, Anushree; Guedj, Jeremie et al. (2015) A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir Ther 20:469-77
Althaus, Christian L; Joos, Beda; Perelson, Alan S et al. (2014) Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. PLoS Comput Biol 10:e1003871
Sherman, Kenneth E; Guedj, Jeremie; Shata, Mohamed Tarek et al. (2014) Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Sci Transl Med 6:246ra98
Graw, Frederik; Balagopal, Ashwin; Kandathil, Abraham J et al. (2014) Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput Biol 10:e1003934
Hernandez-Vargas, Esteban A; Wilk, Esther; Canini, Laetitia et al. (2014) Effects of aging on influenza virus infection dynamics. J Virol 88:4123-31
Canini, Laetitia; Conway, Jessica M; Perelson, Alan S et al. (2014) Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol 10:e1003568
Conway, Jessica M; Perelson, Alan S (2014) A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis. PLoS Comput Biol 10:e1003769
Canini, Laetitia; Perelson, Alan S (2014) Viral kinetic modeling: state of the art. J Pharmacokinet Pharmacodyn 41:431-43
Ciupe, Stanca M; Ribeiro, Ruy M; Perelson, Alan S (2014) Antibody responses during hepatitis B viral infection. PLoS Comput Biol 10:e1003730
Song, Hongshuo; Hora, Bhavna; Bhattacharya, Tanmoy et al. (2014) Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus. PLoS One 9:e102734

Showing the most recent 10 out of 30 publications